Shakeel Modak, MD
Memorial Sloan Kettering Cancer Center
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Shakeel Modak, MD as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 10:42 UTC. Open this list on ClinicalTrials.gov
- Early Ph1NCT03189706 · Study of Chemoimmunotherapy for High-Risk NeuroblastomaMemorial Sloan Kettering Cancer Center · active not recruiting · Neuroblastoma (NB) · principal investigator
- Ph1NCT02650648 · Humanized Anti-GD2 Antibody Hu3F8 and Allogeneic Natural Killer Cells for High-Risk NeuroblastomaMemorial Sloan Kettering Cancer Center · completed · Neuroblastoma, High-Risk · principal investigator
- N/ANCT02307630 · PET Imaging of Solid Tumors Using 124I-Humanized 3F8: A Pilot StudyMemorial Sloan Kettering Cancer Center · active not recruiting · Melanoma, Neuroblastoma, Sarcoma · principal investigator
- Ph2NCT01114555 · Bevacizumab, Irinotecan and Temozolomide for Relapsed or Refractory NeuroblastomaMemorial Sloan Kettering Cancer Center · completed · Neuroblastoma · principal investigator
- Ph1NCT01099644 · Intraperitoneal RIT With 131I-8H9 for Pts With DSRCT and Other Solid Tumors Involving the PeritoneumY-mAbs Therapeutics · terminated · Peritoneal Cancer · principal investigator
- Ph1NCT00877110 · Anti-GD2 3F8 Antibody and Allogeneic Natural Killer Cells for High-Risk NeuroblastomaMemorial Sloan Kettering Cancer Center · completed · Neuroblastoma, Bone Marrow, Sympathetic Nervous System · principal investigator
- N/ANCT00582608 · Tumor Detection Using Iodine-131-Labeled Monoclonal Antibody 8H9Memorial Sloan Kettering Cancer Center · terminated · CNS Cancer, Neuroblastoma, Sarcoma · principal investigator
- Ph1NCT00492167 · Beta-Glucan and Monoclonal Antibody 3F8 in Treating Patients With Metastatic NeuroblastomaMemorial Sloan Kettering Cancer Center · completed · Neuroblastoma · study chair
- Ph1NCT00450827 · Iodine I 131 Monoclonal Antibody 3F8 and Bevacizumab in Treating Patients With Relapsed or Refractory NeuroblastomaMemorial Sloan Kettering Cancer Center · completed · Neuroblastoma · study chair
- Ph1NCT00087009 · Beta-Glucan and Rituximab in Treating Young Patients With Relapsed or Progressive Lymphoma or Leukemia, or Lymphoproliferative Disorder Related to Donor Stem Cell TransplantationMemorial Sloan Kettering Cancer Center · terminated · Leukemia, Lymphoma, Lymphoproliferative Disorder · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 10:42 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
NIH grants that fund their trials
These grant numbers are on the registry records of the trials above. They fund the trial, often through a cooperative group or network, and their principal investigator is usually someone else.
- Cancer Center AdministrationP30CA008748 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI ALEX MACDONALD · fiscal years 2011 to 2026Named on NCT00450827, NCT00087009
Most cited trial papers
PubMed returned no clinical-trial papers for this author name in neuroblastoma.